{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:51:03Z","timestamp":1775577063878,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bpg.2025.102061","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:58:33Z","timestamp":1761674313000},"page":"102061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A narrative review on the frequency, pathophysiology and management of bowel urgency associated with ulcerative colitis"],"prefix":"10.1016","volume":"78","author":[{"given":"Emese","family":"Iv\u00e1ny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadett","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Bacsur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariann","family":"Rutka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mi","family":"G\u00e1lfalvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Szepes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2025.102061_bib1","article-title":"Ulcerative colitis","author":"Lynch","year":"2025"},{"key":"10.1016\/j.bpg.2025.102061_bib2","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.14309\/ajg.0000000000002404","article-title":"Bowel urgency in ulcerative colitis: current perspectives and future directions","volume":"118","author":"Dubinsky","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102061_bib3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.cgh.2023.02.029","article-title":"Identifying, understanding, and managing fecal urgency in inflammatory bowel diseases","volume":"21","author":"Caron","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.102061_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-023-02726-4","article-title":"Bowel urgency in patients with ulcerative colitis and Crohn's Disease: a Cross-Sectional Real-World Survey in Japan","volume":"41","author":"Wang","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.bpg.2025.102061_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.17219\/acem\/68986","article-title":"Stool patterns and symptoms of disordered anorectal function in patients with inflammatory bowel diseases","volume":"27","author":"Petryszyn","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.bpg.2025.102061_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ueg2.12657","article-title":"Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: results from the Swiss fecal urgency survey","volume":"13","author":"Wespi","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.bpg.2025.102061_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","article-title":"Self-reported symptom burden in individuals with inflammatory bowel disease","volume":"10","author":"Farrell","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-230X-12-108","article-title":"Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey","volume":"12","author":"Schreiber","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102061_bib9","doi-asserted-by":"crossref","first-page":"i324","DOI":"10.1093\/ecco-jcc\/jjab232.420","article-title":"P293 insights from patients with Ulcerative Colitis on disease burden: findings from a real-world survey in Europe","volume":"16","author":"Burisch","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib10","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cgh.2023.12.019","article-title":"Fecal urgency in ulcerative colitis: impact on quality of life and psychological well-being in active and inactive disease States","volume":"22","author":"Nigam","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.102061_bib11","first-page":"5","article-title":"Rectal urgency among patients with ulcerative colitis or Crohn's disease: analyses from a Global Survey","author":"Ha","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.bpg.2025.102061_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/jcag\/gwac036.190","article-title":"A190 the impact of bowel urgency on the lives of patients with ulcerative colitis in the US and Europe: communicating Needs and Features of IBD Experiences (CONFIDE) survey","volume":"6","author":"Schreiber","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102061_bib13","article-title":"S705 urgency and its Association with quality of life and clinical outcomes in ulcerative colitis patients","volume":"116","author":"Sninsky","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102061_bib14","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s10620-024-08313-z","article-title":"Effect of suboptimal disease control on patient quality of life: Real-World data from the observational IBD-PODCAST Canada trial","volume":"69","author":"Siffledeen","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2025.102061_bib15","doi-asserted-by":"crossref","first-page":"otae047","DOI":"10.1093\/crocol\/otae047","article-title":"Burden of bowel urgency in patients with ulcerative colitis and Crohn's disease: a real-world global Study","volume":"6","author":"Atreya","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.bpg.2025.102061_bib16","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2024.08.047","article-title":"Multidimensional patient-reported outcomes and quality of life at diagnosis of IBD: a population-based inception cohort Study","volume":"23","author":"Attauabi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.102061_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.14309\/ajg.0000000000001685","article-title":"Urgency and its Association with quality of life and clinical outcomes in patients with ulcerative colitis","volume":"117","author":"Sninsky","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102061_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10620-016-4363-3","article-title":"Perceived emotional and psychological impact of ulcerative colitis on Outpatients in Spain: UC-LIFE Survey","volume":"62","author":"L\u00f3pez-Sanrom\u00e1n","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2025.102061_bib19","article-title":"P0497 faecal incontinence and urgency in IBD patients on biologic therapy in remission: prevalence and risk factors","volume":"19","author":"Jelakovic","year":"2025","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib20","article-title":"Fecal urgency in quiescent IBD is associated with poor quality of life: a cross-sectional study of SPARC IBD Cohort","volume":"166","author":"Dunleavy","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2025.102061_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1023\/A:1005492806777","article-title":"Concerns of patients with inflammatory bowel disease: a review of emerging themes","volume":"45","author":"Casati","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2025.102061_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izae020.169","article-title":"Understanding how patients with moderate-to-severe ulcerative colitis describe the spectrum of bowel urgency definitions: results from qualitative research","volume":"30","author":"Dubinsky","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.102061_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2025.102061_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s41687-024-00800-1","article-title":"Patient perception of bowel urgency and remission in moderately to severely active Crohn's disease or ulcerative colitis: a qualitative study","volume":"8","author":"Gibble","year":"2024","journal-title":"Patient-Rep Outcomes"},{"key":"10.1016\/j.bpg.2025.102061_bib25","article-title":"P0573 the burden of urgency in ulcerative colitis: impact of disease duration and activity","volume":"19","author":"Singeap PhD","year":"2025","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.gastro.2021.09.052","article-title":"Ulcerative colitis patients have reduced rectal compliance compared with non\u2013inflammatory bowel disease controls","volume":"162","author":"Krugliak Cleveland","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2025.102061_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101819","article-title":"Enteric neuro-immune interactions in intestinal health and disease","volume":"70","author":"Van Baarle","year":"2023","journal-title":"Semin Immunol"},{"key":"10.1016\/j.bpg.2025.102061_bib28","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ibd.21422","article-title":"Role of sensory neurons in colitis: increasing evidence for a neuroimmune link in the gut","volume":"17","author":"Engel","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.102061_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gut.52.1.84","article-title":"Changes in chemical coding of myenteric neurones in ulcerative colitis","volume":"52","author":"Neunlist","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2025.102061_bib30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.5604\/17322693.1044747","article-title":"Neural control disturbances of the gastrointestinal tract and visceral pain in inflammatory bowel diseases","volume":"67","author":"Ciesielczyk","year":"2013","journal-title":"Postepy Hig Med Dosw"},{"key":"10.1016\/j.bpg.2025.102061_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adg1668","article-title":"Enteric glia promote visceral hypersensitivity during inflammation through intercellular signaling with gut nociceptors","volume":"16","author":"Morales-Soto","year":"2023","journal-title":"Sci Signal"},{"key":"10.1016\/j.bpg.2025.102061_bib32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI76306","article-title":"Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon","volume":"125","author":"Mawe","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.bpg.2025.102061_bib33","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3748\/wjg.v25.i31.4414","article-title":"Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: prevalence, diagnosis and treatment","volume":"25","author":"Barros","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102061_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10350-004-0774-x","article-title":"Rectal hypersensitivity worsens Stool Frequency, urgency, and lifestyle in patients with urge fecal incontinence","volume":"48","author":"Chan","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.bpg.2025.102061_bib35","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ibd\/izz204","article-title":"Real-world effectiveness of advanced therapies among patients with moderate to severe ulcerative colitis in the United States","volume":"26","author":"Long","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.102061_bib36","first-page":"59","article-title":"A practical clinical approach to the management of high-risk ulcerative colitis","volume":"17","author":"Rubin","year":"2021","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.102061_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000505092","article-title":"Ulcerative colitis: disease burden, impact on daily life, and reluctance to consult medical professionals: results from a Japanese Internet Survey","volume":"5","author":"Hibi","year":"2020","journal-title":"Inflamm Intest Dis"},{"key":"10.1016\/j.bpg.2025.102061_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.crohns.2013.03.005","article-title":"Topical therapy is underused in patients with ulcerative colitis","volume":"8","author":"Seibold","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib39","article-title":"Ulcerative proctitis: an update on the pharmacotherapy and management","volume":"15","author":"Gecse","year":"2014","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.bpg.2025.102061_bib40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2036.1991.tb00520.x","article-title":"Is topical therapy necessary in acute distal colitis? Double\u2010blind comparison of high\u2010dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis","volume":"5","author":"Cobden","year":"1991","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2025.102061_bib41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2013.03.025","article-title":"The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis","volume":"145","author":"Feagan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2025.102061_bib42","first-page":"157","article-title":"Early resolution of bowel urgency by budesonide foam enema results in improved quality of life in patients with ulcerative colitis: a multicenter prospective observational study","volume":"23","author":"Kobayashi","year":"2025","journal-title":"Int Res"},{"key":"10.1016\/j.bpg.2025.102061_bib43","first-page":"812","article-title":"Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study: Inflamm Bowel","volume":"18","author":"Acosta","year":"2012","journal-title":"Dissent"},{"key":"10.1016\/j.bpg.2025.102061_bib44","doi-asserted-by":"crossref","first-page":"i2192","DOI":"10.1093\/ecco-jcc\/jjae190.1386","article-title":"Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world ulcerative colitis cohort","volume":"19","author":"Battat","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/apt.14930","article-title":"Short and long\u2010term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry","volume":"48","author":"Chaparro","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2025.102061_bib46","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/03007995.2023.2244414","article-title":"Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe","volume":"39","author":"Gisbert","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bpg.2025.102061_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.bpg.2025.102061_bib48","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2025.102061_bib49","doi-asserted-by":"crossref","unstructured":"Nyberg L, Halfvarson J, S\u00f6derling J, Ol\u00e9n O, Strid H, Hedin CRH, et al. Prospective observational study of tofacitinib in ulcerative colitis \u2013 analysis of clinical data, fatigue and health-related quality of life during the induction phase n.d.;vol. 18.","DOI":"10.1093\/ecco-jcc\/jjad212.1177"},{"key":"10.1016\/j.bpg.2025.102061_bib50","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/ibd\/izac121","article-title":"Tofacitinib response in ulcerative colitis (TOUR): early response after initiation of tofacitinib therapy in a real-world setting","volume":"29","author":"Long","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.102061_bib51","article-title":"Clinical long-term outcomes of patient-reported outcomes in the prospective real-world tofacitinib response in ulcerative colitis registry","volume":"15","author":"Herfarth","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102061_bib52","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib Therapy reduces Ulcerative Colitis symptoms as early as day 1 of Induction Treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.102061_bib53","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/ibd\/izad016","article-title":"Upadacitinib induction and maintenance therapy improves abdominal pain, bowel urgency, and fatigue in patients with ulcerative colitis: a post hoc analysis of phase 3 data","volume":"29","author":"Danese","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.102061_bib54","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/ecco-jcc\/jjab099","article-title":"Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis","volume":"15","author":"Ghosh","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib55","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/03007995.2025.2494642","article-title":"The real-world effectiveness of ustekinumab in patients with ulcerative colitis in the United States","volume":"41","author":"Burbage","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bpg.2025.102061_bib56","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.3390\/jcm14134590","article-title":"Interleukin 23: pathogenetic involvement and therapeutic target for ulcerative colitis","volume":"14","author":"Parisio","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.bpg.2025.102061_bib57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.bpg.2025.102061_bib58","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2025.102061_bib59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2025.102061_bib60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/jcm13010224","article-title":"The role of IL-23 inhibitors in Crohn's disease","volume":"13","author":"Fanizza","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.bpg.2025.102061_bib61","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/ibd\/izae024","article-title":"Two-Year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension Study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.102061_bib62","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izae253","article-title":"Three-Year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension Study","volume":"31","author":"Sands","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.102061_bib63","article-title":"Mirikizumab demonstrates rapid improvements in bowel urgency severity, bowel urgency frequency, and stool deferral time in patients with moderately-to-severely active Ulcerative Colitis: 12-week interim results from the phase 3b LUCENT-URGE trial","volume":"19","author":"Danese","year":"2025","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib64","article-title":"Impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis","volume":"4","author":"Dubinsky","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.bpg.2025.102061_bib65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s41687-025-00906-0","article-title":"Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab","volume":"9","author":"Clemow","year":"2025","journal-title":"J Patient-Rep Outcomes"},{"key":"10.1016\/j.bpg.2025.102061_bib66","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003420","article-title":"Symptom resolution and meaningful improvement in quality of life with risankizumab in patients with ulcerative colitis: post hoc analysis of the randomized INSPIRE and COMMAND studies","author":"Torres","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102061_bib67","unstructured":"Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, et al. Efficacy and safety of subcutaneous Guselkumab induction therapy in patients with ulcerative colitis: results through week 24 from the phase 3 ASTRO Study n.d."},{"key":"10.1016\/j.bpg.2025.102061_bib68","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/ecco-jcc\/jjae190.0010","article-title":"Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: results through week 12 from the phase 3 ASTRO study","volume":"19","author":"Peyrin-Biroulet","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib69","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2025.102061_bib70","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","article-title":"Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 ELEVATE UC clinical Programme","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.102061_bib71","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/nu16070934","article-title":"Herbal medicines for the treatment of active ulcerative colitis: a systematic review and meta-analysis","volume":"16","author":"Iyengar","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.bpg.2025.102061_bib72","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1002\/jcb.27273","article-title":"The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients' self\u2010reported well\u2010being: a randomized double\u2010blind controlled trial","volume":"119","author":"Masoodi","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bpg.2025.102061_bib73","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.102061_bib74","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jgh.13700","article-title":"Prebiotic inulin\u2010type fructans and galacto\u2010oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders","volume":"32","author":"Wilson","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.102061_bib75","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/10408398.2012.656772","article-title":"Immunological properties of inulin-type fructans","volume":"55","author":"Vogt","year":"2015","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.bpg.2025.102061_bib76","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.3390\/nu13103598","article-title":"Prebiotic galactooligosaccharide supplementation in adults with ulcerative colitis: exploring the impact on peripheral blood gene expression, Gut Microbiota, and clinical symptoms","volume":"13","author":"Wilson","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.bpg.2025.102061_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2023-100055","article-title":"Prebiotic selection influencing inflammatory bowel disease treatment outcomes: a review of the preclinical and clinical evidence","volume":"2","author":"Ariaee","year":"2024","journal-title":"eGastroenterology"},{"key":"10.1016\/j.bpg.2025.102061_bib78","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/nu17081305","article-title":"Beyond the gut: unveiling butyrate's global health impact through gut health and dysbiosis-related conditions: a narrative review","volume":"17","author":"Kalkan","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.bpg.2025.102061_bib79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1046\/j.1365-2362.2003.01130.x","article-title":"Topical butyrate improves efficacy of 5\u2010ASA in refractory distal ulcerative colitis: results of a multicentre trial","volume":"33","author":"Vernia","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bpg.2025.102061_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.03.020","article-title":"A pilot randomized control trial to assess the adjunctive effect of diet on response to advanced therapies in patients with UC","author":"Damas","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.102061_bib81","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41430-019-0549-z","article-title":"The effects of extra virgin olive oil and canola oil on inflammatory markers and gastrointestinal symptoms in patients with ulcerative colitis","volume":"74","author":"Morvaridi","year":"2020","journal-title":"Eur J Clin Nutr"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825000885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825000885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T20:18:01Z","timestamp":1764793081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691825000885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":81,"alternative-id":["S1521691825000885"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2025.102061","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A narrative review on the frequency, pathophysiology and management of bowel urgency associated with ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2025.102061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102061"}}